Buchang Pharma expands production capacity with new venture, license amendment

Shandong Buchang Pharmaceuticals announced its controlling subsidiary, Shandong Buchang Chuanfang Pharmaceutical Co., Ltd., has registered a new subsidiary, Shaanxi Buchang Yishu Pharmaceutical Co., Ltd. The new entity, with a registered capital of 5 million yuan, was established in partnership with Lingyi Shushu (Shaanxi) Internet Technology Co., Ltd. and will be consolidated into Buchang Pharmaceuticals’ financial statements. This follows earlier board approvals and a cooperation agreement.

In a related development, Shandong Buchang Pharmaceuticals also received approval from the Shandong Provincial Medical Products Administration to amend its "Drug Manufacturing License." This allows for increased contract manufacturing, permitting Shandong Buchang Pharmaceuticals to entrust Shandong Kongfu Pharmaceutical Co., Ltd. with the production of Xiaolin Baidusan until May 26, 2028.

This strategic move is expected to optimize Buchang Pharmaceuticals' production structure, maintain stable production capacity, and meet market demand, positively impacting the company's future operations.